| pubmed-article:10394119 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10394119 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10394119 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:10394119 | lifeskim:mentions | umls-concept:C0014582 | lld:lifeskim |
| pubmed-article:10394119 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:10394119 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10394119 | pubmed:dateCreated | 1999-8-5 | lld:pubmed |
| pubmed-article:10394119 | pubmed:abstractText | In vitro data demonstrated a dose-response relationship for doxorubicin in ovarian cancer (OC) cell lines. However, this dose-response question for doxorubicin was never carefully addressed in OC patients. These data and the more favorable toxicity profile of the anthracycline analogue epirubicin prompted us to study high-dose epirubicin (HDE) in relapsed OC patients. | lld:pubmed |
| pubmed-article:10394119 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10394119 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10394119 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10394119 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10394119 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10394119 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10394119 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10394119 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10394119 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10394119 | pubmed:issn | 0030-2414 | lld:pubmed |
| pubmed-article:10394119 | pubmed:author | pubmed-author:KobierskaAA | lld:pubmed |
| pubmed-article:10394119 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:10394119 | pubmed:author | pubmed-author:FornoCC | lld:pubmed |
| pubmed-article:10394119 | pubmed:author | pubmed-author:VermorkenJ... | lld:pubmed |
| pubmed-article:10394119 | pubmed:author | pubmed-author:PiccartM JMJ | lld:pubmed |
| pubmed-article:10394119 | pubmed:author | pubmed-author:ten Bokkel... | lld:pubmed |
| pubmed-article:10394119 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:10394119 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10394119 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:10394119 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10394119 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10394119 | pubmed:pagination | 10-6 | lld:pubmed |
| pubmed-article:10394119 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:meshHeading | pubmed-meshheading:10394119... | lld:pubmed |
| pubmed-article:10394119 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10394119 | pubmed:articleTitle | Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma. | lld:pubmed |
| pubmed-article:10394119 | pubmed:affiliation | University Hospital 'Vrije Universiteit', Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:10394119 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10394119 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10394119 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
